[go: up one dir, main page]

SG11201609285SA - Anti-b7-h1 and anti-ctla-4 antibodies for treating non-small cell lung cancer - Google Patents

Anti-b7-h1 and anti-ctla-4 antibodies for treating non-small cell lung cancer

Info

Publication number
SG11201609285SA
SG11201609285SA SG11201609285SA SG11201609285SA SG11201609285SA SG 11201609285S A SG11201609285S A SG 11201609285SA SG 11201609285S A SG11201609285S A SG 11201609285SA SG 11201609285S A SG11201609285S A SG 11201609285SA SG 11201609285S A SG11201609285S A SG 11201609285SA
Authority
SG
Singapore
Prior art keywords
ctla
antibodies
lung cancer
small cell
cell lung
Prior art date
Application number
SG11201609285SA
Inventor
Rajesh Narwal
Paul Robbins
Joyson Karakunnel
Mohammed M Dar
Original Assignee
Medimmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Ltd filed Critical Medimmune Ltd
Publication of SG11201609285SA publication Critical patent/SG11201609285SA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
SG11201609285SA 2014-05-13 2015-05-12 Anti-b7-h1 and anti-ctla-4 antibodies for treating non-small cell lung cancer SG11201609285SA (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201461992658P 2014-05-13 2014-05-13
US201562105992P 2015-01-21 2015-01-21
US201562114336P 2015-02-10 2015-02-10
PCT/EP2015/060523 WO2015173267A1 (en) 2014-05-13 2015-05-12 Anti-b7-h1 and anti-ctla-4 antibodies for treating non-small cell lung cancer

Publications (1)

Publication Number Publication Date
SG11201609285SA true SG11201609285SA (en) 2016-12-29

Family

ID=53175516

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201609285SA SG11201609285SA (en) 2014-05-13 2015-05-12 Anti-b7-h1 and anti-ctla-4 antibodies for treating non-small cell lung cancer
SG10201810108PA SG10201810108PA (en) 2014-05-13 2015-05-12 Anti-b7-h1 and anti-ctla-4 antibodies for treating non-small cell lung cancer

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10201810108PA SG10201810108PA (en) 2014-05-13 2015-05-12 Anti-b7-h1 and anti-ctla-4 antibodies for treating non-small cell lung cancer

Country Status (27)

Country Link
US (3) US10232040B2 (en)
EP (2) EP3142751B1 (en)
JP (4) JP6648038B2 (en)
KR (4) KR20230165876A (en)
CN (2) CN113230398B (en)
AU (4) AU2015260962B2 (en)
BR (1) BR122023025321A2 (en)
CA (1) CA2947471A1 (en)
CY (1) CY1122642T1 (en)
DK (1) DK3142751T3 (en)
ES (1) ES2749098T3 (en)
GB (1) GB2531094A (en)
HR (1) HRP20191449T1 (en)
HU (1) HUE045965T2 (en)
IL (2) IL248528B (en)
LT (1) LT3142751T (en)
ME (1) ME03493B (en)
MX (1) MX373019B (en)
PL (1) PL3142751T3 (en)
PT (1) PT3142751T (en)
RS (1) RS59134B1 (en)
RU (1) RU2702332C2 (en)
SG (2) SG11201609285SA (en)
SI (1) SI3142751T1 (en)
SM (1) SMT201900544T1 (en)
TW (3) TWI707692B (en)
WO (1) WO2015173267A1 (en)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112016005303A2 (en) * 2013-09-11 2017-09-12 Medimmune Ltd anti-b7-h1 antibodies for tumor treatment
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
RS59134B1 (en) * 2014-05-13 2019-09-30 Medimmune Ltd Anti-b7-h1 and anti-ctla-4 antibodies for treating non-small cell lung cancer
GB2535256A (en) * 2014-08-28 2016-08-17 Medimmune Ltd Combination therapy for PD-L1 negative tumors
WO2016030455A1 (en) * 2014-08-28 2016-03-03 Medimmune Limited Anti-b7-h1 and anti-ctla-4 antibodies for treating non-small lung cancer
JP6826055B2 (en) 2015-03-13 2021-02-03 サイトメックス セラピューティクス インコーポレイテッド Anti-PDL1 antibody, activating anti-PDL1 antibody, and how to use it
TW201735949A (en) 2016-03-24 2017-10-16 千禧製藥公司 Methods of treating gastrointestinal immune-related adverse events in anti-CTLA4 anti-PD-1 combination treatments
US11760803B2 (en) 2016-03-24 2023-09-19 Takeda Pharmaceutical Company Limited Methods of treating gastrointestinal immune-related adverse events in immune oncology treatments
AU2017257505B2 (en) * 2016-04-25 2020-05-14 Medimmune, Llc Compositions comprising coformulation of anti-PD-L1 and Anti-CTLA-4 antibodies
EP3458612B1 (en) 2016-05-17 2023-11-15 Genecentric Therapeutics, Inc. Methods for subtyping of lung adenocarcinoma
CA3024744A1 (en) 2016-05-17 2017-11-23 Genecentric Therapeutics, Inc. Methods for subtyping of lung squamous cell carcinoma
WO2017220989A1 (en) 2016-06-20 2017-12-28 Kymab Limited Anti-pd-l1 and il-2 cytokines
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
WO2018029474A2 (en) 2016-08-09 2018-02-15 Kymab Limited Anti-icos antibodies
KR20230044038A (en) 2016-08-09 2023-03-31 키맵 리미티드 Anti-icos antibodies
EP3510048A1 (en) 2016-09-06 2019-07-17 Mayo Foundation for Medical Education and Research Methods of treating pd-l1 expressing cancer
EP3534947A1 (en) 2016-11-03 2019-09-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
CN110944663A (en) * 2016-11-11 2020-03-31 免疫医疗有限责任公司 anti-PD-L1 and anti-CTLA-4 antibodies for the treatment of non-small cell lung cancer
WO2018098352A2 (en) 2016-11-22 2018-05-31 Jun Oishi Targeting kras induced immune checkpoint expression
JP7300394B2 (en) 2017-01-17 2023-06-29 ヘパリジェニックス ゲーエムベーハー Protein kinase inhibition to promote liver regeneration or reduce or prevent hepatocyte death
MA47509A (en) * 2017-02-16 2019-12-25 Medimmune Llc ANTI-PD-L1 ANTIBODY TREATMENT FOR BLADDER CANCER
BR112019025188A2 (en) 2017-06-01 2020-06-23 Cytomx Therapeutics, Inc. ACTIVABLE ANTI-PDL1 ANTIBODIES AND METHODS OF USE OF THE SAME
GB201709808D0 (en) 2017-06-20 2017-08-02 Kymab Ltd Antibodies
GB201721338D0 (en) 2017-12-19 2018-01-31 Kymab Ltd Anti-icos Antibodies
WO2019122882A1 (en) 2017-12-19 2019-06-27 Kymab Limited Bispecific antibody for icos and pd-l1
AU2018412532B2 (en) * 2018-03-08 2025-05-08 Astrazeneca Ab Compositions and methods for treating late stage lung cancer
WO2021024020A1 (en) 2019-08-06 2021-02-11 Astellas Pharma Inc. Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer
JP7487558B2 (en) 2020-05-25 2024-05-21 船井電機株式会社 Surface light source device and display device
CA3182579A1 (en) 2020-07-07 2022-01-13 Ugur Sahin Therapeutic rna for hpv-positive cancer
TW202245808A (en) 2020-12-21 2022-12-01 德商拜恩迪克公司 Therapeutic rna for treating cancer
WO2022135666A1 (en) 2020-12-21 2022-06-30 BioNTech SE Treatment schedule for cytokine proteins
WO2022135667A1 (en) 2020-12-21 2022-06-30 BioNTech SE Therapeutic rna for treating cancer
TW202304506A (en) 2021-03-25 2023-02-01 日商安斯泰來製藥公司 Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
CA3219336A1 (en) 2021-05-18 2022-11-24 Kymab Limited Uses of anti-icos antibodies
GB202107994D0 (en) 2021-06-04 2021-07-21 Kymab Ltd Treatment of cancer
JP2024525758A (en) 2021-07-13 2024-07-12 ビオンテック・ソシエタス・エウロパエア Multispecific binding agents to CD40 and CD137 in combination therapy for cancer - Patents.com
WO2023051926A1 (en) 2021-09-30 2023-04-06 BioNTech SE Treatment involving non-immunogenic rna for antigen vaccination and pd-1 axis binding antagonists
TW202333802A (en) 2021-10-11 2023-09-01 德商拜恩迪克公司 Therapeutic rna for lung cancer
MX2024004429A (en) * 2021-10-29 2024-05-06 Oncoc4 Inc Anti-ctla-4 antibody dosing regimens.
WO2023083439A1 (en) 2021-11-09 2023-05-19 BioNTech SE Tlr7 agonist and combinations for cancer treatment
EP4525991A1 (en) 2022-05-18 2025-03-26 Kymab Limited Uses of anti-icos antibodies
CN120302979A (en) 2022-12-01 2025-07-11 生物技术公司 Combination therapy of multispecific antibodies targeting CD40 and CD137 with anti-PD1 Ab and chemotherapy
WO2024126457A1 (en) 2022-12-14 2024-06-20 Astellas Pharma Europe Bv Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and immune checkpoint inhibitors
EP4658310A1 (en) 2023-01-30 2025-12-10 Kymab Limited Antibodies
WO2025056180A1 (en) 2023-09-15 2025-03-20 BioNTech SE Methods of treatment using agents binding to epcam and cd137 in combination with pd-1 axis binding antagonists
WO2025121445A1 (en) 2023-12-08 2025-06-12 Astellas Pharma Inc. Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2
WO2025120867A1 (en) 2023-12-08 2025-06-12 Astellas Pharma Inc. Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and anti-vegfr2 antibodies
WO2025120866A1 (en) 2023-12-08 2025-06-12 Astellas Pharma Inc. Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7109003B2 (en) 1998-12-23 2006-09-19 Abgenix, Inc. Methods for expressing and recovering human monoclonal antibodies to CTLA-4
EE05627B1 (en) 1998-12-23 2013-02-15 Pfizer Inc. Human monoclonal antibodies to CTLA-4
US7158164B2 (en) 2003-08-29 2007-01-02 Fuji Photo Film Co., Ltd. Thermal development method and apparatus
AU2011203119C1 (en) * 2005-05-09 2018-06-14 E. R. Squibb & Sons, L.L.C. Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
KR101888321B1 (en) * 2005-07-01 2018-08-13 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. Human monoclonal antibodies to programmed death ligand 1(pd-l1)
EP2007423A2 (en) * 2006-04-05 2008-12-31 Pfizer Products Incorporated Ctla4 antibody combination therapy
WO2008100562A2 (en) * 2007-02-14 2008-08-21 Medical College Of Georgia Research Institute, Inc. Indoleamine 2,3-dioxygenase, pd-1/pd-l pathways, and ctla4 pathways in the activation of regulatory t cells
LT3279215T (en) 2009-11-24 2020-04-10 Medimmune Limited TARGET BINDING AGENTS BEFORE B7-H1
CN102000947B (en) * 2010-10-14 2012-06-06 沈阳飞机工业（集团）有限公司 Method for milling two half bushes
LT3757126T (en) 2010-11-05 2025-12-10 Novartis Ag Methods of treating psoriatic arthritis using il-17 antagonists
CN101975831B (en) * 2010-11-25 2012-09-05 中国检验检疫科学研究院 Method for measuring zinc benzenesulfonate in cosmetics through high performance liquid chromatography (HPLC)
TWI496886B (en) * 2011-06-24 2015-08-21 Taipei Veteran General Hospital Method for enhancing immune resposne in the treatment of infectious and malignant diseases
US9863935B2 (en) * 2012-05-08 2018-01-09 H. Lee Moffitt Cancer And Research Institute, Inc. Predictive biomarkers for CTLA-4 blockade therapy and for PD-1 blockade therapy
WO2013172926A1 (en) * 2012-05-14 2013-11-21 Yale University Immune biomarkers and assays predictive of clinical response to immunotherapy for cancer
WO2013173223A1 (en) * 2012-05-15 2013-11-21 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting pd-1/pd-l1 signaling
CA2889182A1 (en) 2012-10-26 2014-05-01 The University Of Chicago Synergistic combination of immunologic inhibitors for the treatment of cancer
US9107960B2 (en) * 2012-12-13 2015-08-18 Immunimedics, Inc. Antibody-SN-38 immunoconjugates with a CL2A linker
RU2019138702A (en) * 2013-03-01 2020-01-27 Астекс Фармасьютикалз, Инк. DRUG COMBINATIONS
RS59134B1 (en) * 2014-05-13 2019-09-30 Medimmune Ltd Anti-b7-h1 and anti-ctla-4 antibodies for treating non-small cell lung cancer
WO2016030455A1 (en) * 2014-08-28 2016-03-03 Medimmune Limited Anti-b7-h1 and anti-ctla-4 antibodies for treating non-small lung cancer
PT3218406T (en) * 2014-11-10 2021-06-17 Medimmune Ltd Binding molecules specific for cd73 and uses thereof
ES2813580T3 (en) * 2015-04-17 2021-03-24 Bristol Myers Squibb Co Compositions comprising a combination of ipilimumab and nivolumab
US20160347848A1 (en) * 2015-05-28 2016-12-01 Medimmune Limited Therapeutic combinations and methods for treating neoplasia
AU2017257505B2 (en) * 2016-04-25 2020-05-14 Medimmune, Llc Compositions comprising coformulation of anti-PD-L1 and Anti-CTLA-4 antibodies
MA47509A (en) * 2017-02-16 2019-12-25 Medimmune Llc ANTI-PD-L1 ANTIBODY TREATMENT FOR BLADDER CANCER
US12042527B2 (en) * 2019-01-08 2024-07-23 Modernatx, Inc. Use of mRNAs encoding OX40L, IL-23 and IL-36gamma in combination with immune checkpoint blockade for treating particular cancers

Also Published As

Publication number Publication date
JP2021098734A (en) 2021-07-01
DK3142751T3 (en) 2019-10-14
RU2016148645A3 (en) 2018-12-21
AU2020230309B2 (en) 2023-04-20
KR20170003575A (en) 2017-01-09
LT3142751T (en) 2019-09-25
IL248528A0 (en) 2016-12-29
US20230115328A1 (en) 2023-04-13
BR112016026197A2 (en) 2018-02-20
KR20230165876A (en) 2023-12-05
RU2702332C2 (en) 2019-10-08
ME03493B (en) 2020-01-20
SI3142751T1 (en) 2019-09-30
SG10201810108PA (en) 2018-12-28
PT3142751T (en) 2019-10-25
EP3142751B1 (en) 2019-08-07
RU2016148645A (en) 2018-06-19
IL276481B (en) 2022-06-01
IL248528B (en) 2020-08-31
MX373019B (en) 2020-03-31
CN106456756B (en) 2021-04-23
SMT201900544T1 (en) 2019-11-13
AU2023204286B2 (en) 2025-02-06
HUE045965T2 (en) 2020-01-28
JP6648038B2 (en) 2020-02-14
ES2749098T3 (en) 2020-03-19
TW201545759A (en) 2015-12-16
BR122023025321A2 (en) 2024-02-20
JP2023052607A (en) 2023-04-11
US10232040B2 (en) 2019-03-19
HRP20191449T1 (en) 2019-11-15
JP7519477B2 (en) 2024-07-19
EP3603748A1 (en) 2020-02-05
IL276481A (en) 2020-09-30
US11446377B2 (en) 2022-09-20
CA2947471A1 (en) 2015-11-19
JP2020090509A (en) 2020-06-11
JP2017520520A (en) 2017-07-27
KR102333658B1 (en) 2021-12-01
CN106456756A (en) 2017-02-22
CN113230398B (en) 2025-01-03
KR20210149870A (en) 2021-12-09
AU2020230309A1 (en) 2020-10-01
AU2015260962B2 (en) 2020-06-11
AU2015260962A1 (en) 2016-11-24
AU2023204286A1 (en) 2023-07-27
TWI707692B (en) 2020-10-21
KR20220162844A (en) 2022-12-08
RU2019129614A3 (en) 2021-12-27
US20150328311A1 (en) 2015-11-19
TW202123967A (en) 2021-07-01
PL3142751T3 (en) 2019-12-31
TW202233239A (en) 2022-09-01
CN113230398A (en) 2021-08-10
GB201508097D0 (en) 2015-06-24
AU2025202908A1 (en) 2025-05-15
RU2019129614A (en) 2020-07-16
RS59134B1 (en) 2019-09-30
EP3142751A1 (en) 2017-03-22
TWI780994B (en) 2022-10-11
WO2015173267A1 (en) 2015-11-19
MX2016014189A (en) 2017-05-04
US20190240324A1 (en) 2019-08-08
GB2531094A (en) 2016-04-13
CY1122642T1 (en) 2021-03-12

Similar Documents

Publication Publication Date Title
IL276481B (en) Anti-b7-h1 and anti-ctla-4 antibodies for treating non-small cell lung cancer
IL267803A (en) Methods of treating cancer with anti-tim-3 antibodies
IL252610A0 (en) Methods and compositons for treating cancer
IL253462B2 (en) Treatment of cancer with anti-lap monoclonal antibodies
PT3063173T (en) Specific anti-cd38 antibodies for treating human cancers
EP3177292A4 (en) Compounds and methods for treating cancer
IL252716A0 (en) Anti-csf1r antibodies for treating pvns
TWI560201B (en) Bi-specific antibodies for treating cancer
EP3191128A4 (en) Uses of anti-her3 antibodies for treating cancer
IL246607A0 (en) Improved cell compositions and methods for cancer therapy
IL262656A (en) Nanoliposomal irinotecan for use in treating small cell lung cancer
IL250507B (en) Anti-ck8 antibodies for use in the treatment of cancers
IL255079A0 (en) Methods for treating lung cancer
IL246558A0 (en) Novel methods for treating cancer
EP3119426A4 (en) Methods and materials for treating cancer
EP3119427A4 (en) Methods and materials for treating cancer
EP3240566A4 (en) Humanized alpha-enolase specific antibodies and methods of uses in cancer therapy
EP3273970A4 (en) Methods and materials for treating cancer
EP3538142A4 (en) Anti-pd-l1 and anti-ctla-4 antibodies for treating non-small cell lung cancer
GB201411393D0 (en) Agents and methods for determining colorectal cancer status
EP3177637B8 (en) Kpv for treating colorectal cancer and ibd
GB201414904D0 (en) Materials and methods for treating cancer
HK1233707A1 (en) Reagents and methods for breast cancer detection